Helicobacter pylori and gastro-oesophageal reflux disease

Lancet

Volumn 368, Issue 9540, 2006, Pages 986-

  Kountouras, Jannis ^a   Zavos, Christos ^a   Chatzopoulos, Dimitrios ^a   Katsinelos, Panagiotis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GASTRIN; NITRIC OXIDE; PROSTAGLANDIN;

DEVELOPED COUNTRY; DUODENUM ULCER; ESOPHAGUS MUCOSA; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HORMONE RELEASE; HUMAN; LETTER; LOWER ESOPHAGUS SPHINCTER PRESSURE; MICROBIAL ACTIVITY; PATHOGENESIS; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH PH; STOMACH PROTECTION;

EID: 33748469685     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69405-1     Document Type: Letter

References (5)

1. Moayyedi P., and Talley N. Gastro-oesophageal reflux disease. Lancet 367 (2006) 2086-2100
2. Graham D. Helicobacter pylori is not and never was "protective" against anything, including GERD. Dig Dis Sci 48 (2003) 629-630
3. Kountouras J., Zavos C., and Chatzopoulos D. H pylori infection and reflux oesophagitis. Gut 53 (2004) 912
4. Kountouras J., Zavos C., and Chatzopoulos D. Induction of interleukin-8 expression by Helicobacter pylori infection in patients with endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol 99 (2004) 2500-2501
5. Schwizer W., Thumshirn M., Dent J., et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 357 (2001) 1738-1742